Market closed

Achieve Life Sciences/$ACHV

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Achieve Life Sciences

Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.

Ticker

$ACHV

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Vancouver, Canada

Employees

Website

www.achievelifesciences.com

ACHV Metrics

BasicAdvanced

$108M

-

-$1.15

1.58 -

Price and volume

Market cap

$108M

Beta

1.58

52-week high

$5.59

52-week low

$3.12

Average daily volume

213K

Financial strength

Current ratio

6.779

Quick ratio

6.389

Long term debt to equity

31.305

Total debt to equity

31.375

Interest coverage (TTM)

-11.29%

Management effectiveness

Return on assets (TTM)

-54.09%

Return on equity (TTM)

-186.03%

Valuation

Price to book

3.45

Price to tangible book (TTM)

3.7

Price to free cash flow (TTM)

-3.628

Growth

Earnings per share change (TTM)

-42.26%

3-year earnings per share growth (CAGR)

-36.62%

What the Analysts think about ACHV

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Achieve Life Sciences stock.

ACHV Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

ACHV Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

ACHV News

AllArticlesVideos

Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

GlobeNewsWire·5 days ago

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

GlobeNewsWire·1 week ago

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

GlobeNewsWire·1 week ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ACHV

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Achieve Life Sciences stock?

Achieve Life Sciences (ACHV) has a market cap of $108M as of January 15, 2025.

What is the P/E ratio for Achieve Life Sciences stock?

The price to earnings (P/E) ratio for Achieve Life Sciences (ACHV) stock is 0 as of January 15, 2025.

Does Achieve Life Sciences stock pay dividends?

No, Achieve Life Sciences (ACHV) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Achieve Life Sciences dividend payment date?

Achieve Life Sciences (ACHV) stock does not pay dividends to its shareholders.

What is the beta indicator for Achieve Life Sciences?

Achieve Life Sciences (ACHV) has a beta rating of 1.58. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.